JP2007516966A - 合成hla結合ペプチド類似体及びその使用方法 - Google Patents

合成hla結合ペプチド類似体及びその使用方法 Download PDF

Info

Publication number
JP2007516966A
JP2007516966A JP2006542741A JP2006542741A JP2007516966A JP 2007516966 A JP2007516966 A JP 2007516966A JP 2006542741 A JP2006542741 A JP 2006542741A JP 2006542741 A JP2006542741 A JP 2006542741A JP 2007516966 A JP2007516966 A JP 2007516966A
Authority
JP
Japan
Prior art keywords
seq
cells
cancer
synthetic peptide
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006542741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516966A5 (cg-RX-API-DMAC7.html
Inventor
シェインバーグ、デイビッド
ピニラ−イバーズ、ジャビア
Original Assignee
スローン−ケターリング インスティチュート フォー キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34652399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007516966(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by スローン−ケターリング インスティチュート フォー キャンサー リサーチ filed Critical スローン−ケターリング インスティチュート フォー キャンサー リサーチ
Publication of JP2007516966A publication Critical patent/JP2007516966A/ja
Publication of JP2007516966A5 publication Critical patent/JP2007516966A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006542741A 2003-12-01 2004-11-30 合成hla結合ペプチド類似体及びその使用方法 Pending JP2007516966A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52595503P 2003-12-01 2003-12-01
PCT/US2004/040347 WO2005053618A2 (en) 2003-12-01 2004-11-30 Synthetic hla binding peptide analogues and uses thereof

Publications (2)

Publication Number Publication Date
JP2007516966A true JP2007516966A (ja) 2007-06-28
JP2007516966A5 JP2007516966A5 (cg-RX-API-DMAC7.html) 2008-01-17

Family

ID=34652399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542741A Pending JP2007516966A (ja) 2003-12-01 2004-11-30 合成hla結合ペプチド類似体及びその使用方法

Country Status (7)

Country Link
US (3) US7488718B2 (cg-RX-API-DMAC7.html)
EP (2) EP2478913A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007516966A (cg-RX-API-DMAC7.html)
AU (1) AU2004294345B2 (cg-RX-API-DMAC7.html)
CA (1) CA2548135C (cg-RX-API-DMAC7.html)
ES (1) ES2402184T5 (cg-RX-API-DMAC7.html)
WO (1) WO2005053618A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512866A (ja) * 2012-01-13 2015-04-30 メモリアル スローン−ケタリング キャンサー センター 免疫原性wt1ペプチド及びその使用方法
JPWO2021230247A1 (cg-RX-API-DMAC7.html) * 2020-05-12 2021-11-18

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127409A1 (en) * 2003-12-01 2006-06-15 Scheinberg David A Bcr-abl vaccines and methods of use thereof
ES2402184T5 (es) * 2003-12-01 2016-10-25 Sloan-Kettering Institute For Cancer Research Análogos de péptidos de unión a HLA sintéticos y sus usos
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) * 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
JP2010504332A (ja) * 2006-09-19 2010-02-12 ヒューマン バイオモレキュラル リサーチ インスティテュート アルツハイマー病の診断方法及び遺伝子マーカー
MX352947B (es) * 2007-02-27 2017-12-14 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
US20100255020A1 (en) * 2007-11-20 2010-10-07 Nec Corporation Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them
WO2009072610A1 (ja) * 2007-12-05 2009-06-11 International Institute Of Cancer Immunology, Inc. 癌ワクチン組成物
CA2760041A1 (en) * 2008-05-14 2009-11-19 Simons Haplomics Limited Methods and compositions for the treatment of cancer
WO2012027379A2 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2013018778A1 (ja) 2011-07-29 2013-02-07 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US20240408197A1 (en) * 2015-11-20 2024-12-12 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer
HUE059694T2 (hu) 2015-11-20 2022-12-28 Memorial Sloan Kettering Cancer Center Készítmény rák kezelésére
US20190209669A1 (en) 2016-08-23 2019-07-11 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Wt1ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
US12059463B2 (en) 2017-10-24 2024-08-13 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
TW202315645A (zh) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 用以處置或預防癌症之醫藥組合物及方法
CN114149970B (zh) * 2021-11-09 2024-06-18 因诺伟(北京)生物医疗科技有限公司 一种外周血造血干细胞来源致敏树突状细胞的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035438A1 (en) * 1995-05-08 1996-11-14 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
WO2003037060A2 (en) * 2001-10-30 2003-05-08 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
JP2003524021A (ja) * 2000-02-22 2003-08-12 コリクサ コーポレイション 悪性中皮腫の診断および治療のための組成物および方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
ES2402184T5 (es) * 2003-12-01 2016-10-25 Sloan-Kettering Institute For Cancer Research Análogos de péptidos de unión a HLA sintéticos y sus usos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035438A1 (en) * 1995-05-08 1996-11-14 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
JP2003524021A (ja) * 2000-02-22 2003-08-12 コリクサ コーポレイション 悪性中皮腫の診断および治療のための組成物および方法
WO2003037060A2 (en) * 2001-10-30 2003-05-08 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010051096, GAO, L. et al., ""Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for", BLOOD, 20000401, Vol.95, No.7, P.2198−2203 *
JPN6010051098, ""Leukemia. 1996 Apr;10(4):693−9."", [online], 19960401, PMID: 8618449,, NCBI *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512866A (ja) * 2012-01-13 2015-04-30 メモリアル スローン−ケタリング キャンサー センター 免疫原性wt1ペプチド及びその使用方法
JP2018104438A (ja) * 2012-01-13 2018-07-05 メモリアル スローン ケタリング キャンサー センター 免疫原性wt1ペプチド及びその使用方法
JPWO2021230247A1 (cg-RX-API-DMAC7.html) * 2020-05-12 2021-11-18
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
JP7153287B2 (ja) 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
JP2022180513A (ja) * 2020-05-12 2022-12-06 住友ファーマ株式会社 癌を処置するための医薬組成物
JP7209986B2 (ja) 2020-05-12 2023-01-23 住友ファーマ株式会社 癌を処置するための医薬組成物

Also Published As

Publication number Publication date
AU2004294345B2 (en) 2012-02-23
ES2402184T5 (es) 2016-10-25
EP1708732B1 (en) 2013-01-02
US7488718B2 (en) 2009-02-10
EP2478913A1 (en) 2012-07-25
US20100239547A1 (en) 2010-09-23
WO2005053618A2 (en) 2005-06-16
CA2548135C (en) 2014-04-22
ES2402184T3 (es) 2013-04-29
US20050119185A1 (en) 2005-06-02
US20060084609A1 (en) 2006-04-20
WO2005053618A3 (en) 2006-02-23
AU2004294345A1 (en) 2005-06-16
EP1708732A4 (en) 2009-09-02
CA2548135A1 (en) 2005-06-16
EP1708732B2 (en) 2016-05-18
EP1708732A2 (en) 2006-10-11
US7598221B2 (en) 2009-10-06

Similar Documents

Publication Publication Date Title
US7488718B2 (en) Synthetic HLA binding peptide analogues and uses thereof
JP4406607B2 (ja) ペプチド及びこれを含む医薬
CN110078813B (zh) 免疫原性wt-1肽和其使用方法
RU2721574C2 (ru) Вакцинная композиция против злокачественной опухоли
JP5230579B2 (ja) 癌抑制遺伝子wt1の産物に基づく癌抗原
US20240368220A1 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2003106682A1 (ja) Hla−a24拘束性癌抗原ペプチド
JPWO2005095598A1 (ja) Wt1由来の癌抗原ペプチド
CN108676069A (zh) 免疫原性wt-1肽及其使用方法
JP4051602B2 (ja) 腫瘍抗原
CN1849395B (zh) 来源于Livin的HLA-A24结合性癌抗原肽
WO2007120603A2 (en) Immunogenic bcr-abl peptides and methods of use thereof
JP4414163B2 (ja) Psa由来のhla−a24結合性癌抗原ペプチド
HK40100878A (en) Immunogenic wt-1 peptides and methods of use thereof
HK40012212A (en) Immunogenic wt-1 peptides and methods of use thereof
AU2012202819A1 (en) Synthetic HLA binding peptide analogues and uses thereof
US20060127409A1 (en) Bcr-abl vaccines and methods of use thereof
HK40012212B (en) Immunogenic wt-1 peptides and methods of use thereof
Myers Custom designed MHC binding peptides for cancer immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110215